Not a traditional drug phase: Commercially available MicroVention Intracranial Aneurysm Treatment Devices for Cerebral Aneurysm
To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of commercially available MicroVention devices used for the endovascular treatment of intracranial aneurysms (IA) at the direction of the treating physician.
Official registry: https://clinicaltrials.gov/study/NCT06215105 · Microvention-Terumo, Inc. · enrollment listed as 750
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 750 people at 27 sites. Taking part typically means using or being fitted with a device plus check-ins.
Official title (unrewritten)
Complex Aneurysm Registry - Real-World Evidence Data Collection for Intracranial Aneurysm Treatment Devices
Interventions: Commercially available MicroVention Intracranial Aneurysm Treatment Devices
Primary outcome (registry wording): RROC
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Patient must have a single ruptured or unruptured IA for which endovascular treatment has been determined appropriate
- Patient must be considered by the treating physician to be available for and able to complete study follow-up visits
Who the registry excludes
- Target aneurysm has been previously treated via surgical or endovascular means
- Patient is enrolled in another device or drug study in which participation could confound study results
- Patient has a life expectancy of less than 1 year due to other illness or condition (in addition to an intracranial aneurysm)
- Patient has been previously enrolled into this study
Public study contact (from the registry)
Robert Gash
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
27 listed- Walnut Creek Medical Center — Walnut Creek, California (recruiting)
- Swedish Medical Center — Englewood, Colorado (recruiting)
- Hartford Hospital — Hartford, Connecticut (recruiting)
- Broward Health Medical Center — Fort Lauderdale, Florida (recruiting)
- Memorial Regional Hospital — Hollywood, Florida (recruiting)
- Baptist Medical Center, Jacksonville — Jacksonville, Florida (recruiting)
- Mount Sinai Medical Center - Miami — Miami Beach, Florida (recruiting)
- Orlando Regional Medical Center — Orlando, Florida (recruiting)
- Tampa General Hospital — Tampa, Florida (recruiting)
- The Queen's Medical Center Neuroscience Institute — Honolulu, Hawaii (recruiting)
- University of Iowa Hospitals & Clinics — Iowa City, Iowa (recruiting)
- Norton Neuroscience Institute — Louisville, Kentucky (recruiting)
FAQ about this NCT record
Is NCT06215105 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT06215105?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT06215105?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary